Moss Genomics Reports Bitcoin Cash (BCH) Mining Activity

Vancouver, British Columbia–(Newsfile Corp. – January 5, 2026) – Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the “Company” or “Moss”) has announced it has mined a block on the Bitcoin Cash (“BCH”) blockchain using proprietary mining infrastructure operated by the Company. BCH block #931,986 was mined on Jan 1, 2026 with miner ID […]

Charlie’s Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access

SBX Product Line Will Feature First-Ever AI-Powered Blockchain-Based Age-Gating System for Vape Products IKE’s patented biometric BLE Bluetooth chip and blockchain-based app will enable Charlie’s to ensure that underage individuals will not be able to activate or utilize the Company’s age-gated products. The IKE Licensing Agreement provides CHUC with a first mover advantage in youth

RedCloud To Announce FY2025 Results, $50m Turkey Update and 2026 Guidance on January 14

(NASDAQ:RCT), LONDON, Jan. 05, 2026 (GLOBE NEWSWIRE) — RedCloud Holdings plc (NASDAQ: RCT) (“RedCloud” or the “Company”), the AI powered company building an intelligent infrastructure for global trade, today announced that it will publish preliminary unaudited financial results for full-year 2025 on Wednesday, January 14, 2026. This announcement will include an update on the company's

Real Matters to Hold Virtual Annual and Special Meeting on February 5, 2026

(TSX:REAL), TORONTO, Jan. 05, 2026 (GLOBE NEWSWIRE) — Real Matters Inc. (“Real Matters”), a leading network management services provider for the mortgage lending and insurance industries, will be holding its Annual and Special Meeting (the “Meeting”) on Thursday, February 5, 2026 at 10:00 a.m. (Eastern Standard Time). The Meeting will be conducted online only, via

Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Concurrent $15 Million Investment at $180 Million Valuation

(NASDAQ:IINN), RA'ANANA, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) — Inspira(TM) Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced it has entered into a non-binding term sheet (the “Term Sheet”), outlining the principal terms of a proposed two-part transaction that would include the acquisition

Cosmos Health Enters Manufacturing Agreement with Libytec for PathMuscle Medicine, with Five-Year Volumes Expected to Exceed 1.2 Million Units

(NASDAQ:COSM), CHICAGO, Jan. 05, 2026 (GLOBE NEWSWIRE) — Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Cana Laboratories, has entered into a manufacturing and supply agreement to undertake the full end-to-end production of the pharmaceutical product PathMuscle for Libytec Pharmaceutical

Polymarket and Parcl Announce Partnership to Launch Real Estate Prediction Markets Powered by Parcl Indices

NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) — Parcl, the real-time housing data and onchain real estate platform, and Polymarket, the world's largest prediction market, today announced a partnership to bring Parcl's daily housing price indices to a new suite of real estate prediction markets on Polymarket. The partnership will introduce housing-focused markets that settle

INSP Investors Have Opportunity to Lead Inspire Medical Systems, Inc. Securities Fraud Lawsuit with the Schall Law Firm

(NYSE:INSP), LOS ANGELES, Jan. 05, 2026 (GLOBE NEWSWIRE) — The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Inspire Medical Systems, Inc. (“Inspire” or “the Company”) (NYSE: INSP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder

Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)

(NasdaqGM:CHRS), -Coherus Oncology formally introduces non-proprietary name: tagmokitug- -Publication shows picomolar affinity for CCR8 with no off-target binding and proof-of- mechanism in preclinical and clinical studies- -Data show CCR8 target is present with high prevalence and density in many solid tumors- REDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) — Coherus Oncology, Inc. (NASDAQ: CHRS)

Scroll to Top